GLPBio

STF 31

Catalog No.: GC14803Purity:>98.00%
STF 31 is a cell-permeable inhibitor of glucose transporter 1 (GLUT1) with an IC₅₀ of 1μM.

Products are for research use only. Not for human use. We do not sell to patients.


STF 31
Cas No.: 724741-75-7
10mM (in 1mL DMSO)In Stock
$85.00
1
5mgIn Stock
$48.00
1
10mgIn Stock
$77.00
1
25mgIn Stock
$147.00
1
50mgIn Stock
$228.00
1
100mgIn Stock
$333.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

STF 31 is a cell-permeable inhibitor of glucose transporter 1 (GLUT1) with an IC₅₀ of 1μM[1]. GLUT1 is a key transporter responsible for glucose uptake and plays an essential role in maintaining glycolytic metabolism[2]. STF 31 can inhibit nicotinamide phosphoribosyltransferase (NAMPT), thereby disrupting glycolysis and inducing cytotoxicity[3].

In vitro, STF 31 (0-10μM) treatment inhibited the glucose uptake capacity of B6M7 cells in a dose-dependent manner within 24h without significantly affecting cell viability[4]. STF 31 (30μM) treatment of MCF-7 cells for 48h significantly suppressed glycolysis and induced apoptosis[5]. STF 31 (2, 4, and 8μM) treatment of rheumatoid arthritis fibroblast-like synoviocytes (RAFLs) for 24-72h inhibited cell proliferation in a time- and dose-dependent manner[6].

In vivo, STF 31 (10mg/kg), administered via intraperitoneal injection (twice daily for the first 2 days, followed by once daily for the next 3 days), had no significant effects on body weight, behavior, or ERG responses in normal mice. In a light-induced model, STF 31 significantly inhibited microglial activation in CX3CR1gfp/+ mice and alleviated retinal degeneration[4]. Intraperitoneal co-administration of STF 31 (10mg/kg) and dexamethasone in normal mice for 4h significantly promoted the accumulation of necrotic thymocytes[7].

References:
[1] Chan D A, Sutphin P D, Nguyen P, et al. Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality[J]. Sci Transl Med, 2011, 3(94).
[2] Wu Q, ba-alawi W, Deblois G, et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer[J]. Nat Commun, 2020, 11(1).
[3] Adams D J, Ito D, Rees M G, et al. NAMPT Is the Cellular Target of STF 31-Like Small-Molecule Probes[J]. Acs Chem Biol, 2014, 9(10): 2247-2254.
[4] Wang L X, Pavlou S, Du X, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis[J]. Mol Neurodegener, 2019, 14.
[5] Xintaropoulou C, Ward C, Wise A, et al. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models[J]. Oncotarget, 2015, 6(28): 25677-25695.
[6] Hou Hou, Lü Xing, Zhang Na, et al. Mechanism Analysis of the Effect of STF 31 on Proliferation and Apoptosis of Fibroblast-like Synoviocytes in Rheumatoid Arthritis [J]. Anatomical Research, 2022, 44(06): 525-531
[7] Morioka S, Perry JSA, Raymond MH, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release[J]. Nature, 2018, 563(7733): 714-718.

Protocol

Cell experiment [1]:

Cell lines

B6M7

Preparation Method

B6M7 cells were seeded into 96-well plates with 6000 cells per well and cultured for 24h. They were treated with different concentrations of STF 31(0, 0.01, 0.1, 1, 5, and 10μM).for 24 h to 48 h.Cells were washed twice with PBS and incubated in serum-free DMEM overnight prior to the assay. Glucose uptake was measured using a Glucose Uptake Assay Kit (ab136955, Abcam) according to the manufacturer’s instructions, and fluorescence was detected using a FLUOstar Omega microplate reader (BMG Labtech). Cell viability was assessed using the AlamarBlue® assay (Thermo Fisher Scientific) following the manufacturer’s protocol.

Reaction Conditions

0, 0.01, 0.1, 1, 5, and 10μM; 24 h, 48 h.

Applications

STF 31 dose-dependently suppressed glucose uptake in B6M7 cells without affecting cell viability.

Animal experiment [1]:

Animal models

C57BL/6J and CX3CR1gfp/+ mice

Preparation Method

C57BL/6 J mice received intraperitoneal STF 31 at 10 mg/kg twice daily for 2 days and once daily for a further 3 days, with DMSO-treated mice as controls. Body weight and electroretinography were assessed on day 6, and eyes were collected for immunohistochemistry (4 mice per group). CX3CR1gfp/+mice were given the same STF 31 regimen starting 1 day prior to light exposure. After 16 h of dark adaptation, pupil dilation, and anesthesia, mice were exposed to 50,000 lx focal white light for 10 min. Clinical and immunohistochemical analyses were performed after treatment (5 mice per group).

Dosage form

10mg/kg, twice daily for 2 days, followed by once daily for another 3 days; i.p.

Applications

STF 31 treatment improved photoreceptor survival and attenuated microglial activation in CX3CR1gfp/+ mice, without inducing retinal cell death in C57BL/6J mice.

References:
[1] Wang L X, Pavlou S, Du X, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis[J]. Mol Neurodegener, 2019, 14.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
724741-75-7
Chemical Name
4-((4-(tert-butyl)phenylsulfonamido)methyl)-N-(pyridin-3-yl)benzamide
SMILES
O=S(NCC1=CC=C(C(NC2=CC=CN=C2)=O)C=C1)(C3=CC=C(C=C3)C(C)(C)C)=O
Molecular Formula
C23H25N3O3S
Molecular Weight
423.53
Solubility
≥ 42.4mg/mL in DMSO
Storage
Store at RT
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for STF 31

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%